Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
Prelude Therapeutics (Nasdaq: PRLD) has announced its participation in the upcoming Citizens JMP Securities Hematology and Oncology Summit, scheduled for December 2, 2024. The virtual event will feature a fireside chat at 11:30 a.m. ET with CEO Kris Vaddi, Ph.D., and President/CMO Jane Huang, M.D. The session will be available via webcast on the company's website and archived for 90 days.
Prelude Therapeutics specializes in precision oncology, developing innovative medicines for high-unmet cancer patient needs. Their pipeline includes first-in-class SMARCA2 degraders (both IV and oral) and a CDK9 inhibitor. The company is also advancing Precision ADCs through partnerships.
Prelude Therapeutics (Nasdaq: PRLD) ha annunciato la sua partecipazione al prossimo Citizens JMP Securities Hematology and Oncology Summit, previsto per il 2 dicembre 2024. L'evento virtuale presenterà una conversazione informale con il CEO Kris Vaddi, Ph.D., e il Presidente/CMO Jane Huang, M.D., alle 11:30 ET. La sessione sarà disponibile in webcast sul sito web dell'azienda e archiviata per 90 giorni.
Prelude Therapeutics si specializza nell'oncologia di precisione, sviluppando farmaci innovativi per soddisfare le elevate esigenze non soddisfatte dei pazienti affetti da cancro. Il loro portafoglio include degradatori SMARCA2 di prima classe (sia IV che orali) e un inibitore di CDK9. L'azienda sta anche avanzando con gli ADC di Precisione attraverso partnership.
Prelude Therapeutics (Nasdaq: PRLD) ha anunciado su participación en la próxima Cumbre de Hematología y Oncología de JMP Securities, programada para el 2 de diciembre de 2024. El evento virtual contará con una charla junto al fuego a las 11:30 a.m. ET con el CEO Kris Vaddi, Ph.D., y la Presidenta/CMO Jane Huang, M.D. La sesión estará disponible a través de un webcast en el sitio web de la compañía y archivada por 90 días.
Prelude Therapeutics se especializa en oncología de precisión, desarrollando medicamentos innovadores para satisfacer las altas necesidades insatisfechas de los pacientes con cáncer. Su cartera incluye degradadores SMARCA2 de primera clase (tanto IV como orales) y un inhibidor de CDK9. La empresa también está avanzando con los ADC de Precisión a través de asociaciones.
프렐뤼드 테라퓨틱스 (Nasdaq: PRLD)는 2024년 12월 2일 예정된 시티즌 JMP 증권 혈액학 및 종양학 정상 회담에 참여한다고 발표했습니다. 이 가상 이벤트에서는 오전 11시 30분 ET에 CEO인 크리스 바디 박사와 사장 겸 CMO인 제인황 박사가 대화하는 시간이 예정되어 있습니다. 이 세션은 회사 웹사이트를 통해 웹캐스트로 제공되며 90일 동안 아카이브됩니다.
프렐뤼드 테라퓨틱스는 정밀 종양학을 전문으로 하며, 높은 미충족 암 환자 요구를 충족하기 위한 혁신적인 의약품을 개발하고 있습니다. 그들의 파이프라인에는 1세대 SMARCA2 분해제(IV 및 경구 모두)와 CDK9 억제가 포함되어 있습니다. 이 회사는 또한 파트너십을 통해 정밀 ADC를 발전시키고 있습니다.
Prelude Therapeutics (Nasdaq: PRLD) a annoncé sa participation au prochain Sommet de l'Hématologie et de l'Oncologie de Citizens JMP Securities, prévu pour le 2 décembre 2024. L'événement virtuel comportera une discussion informelle à 11 h 30 ET avec le PDG Kris Vaddi, Ph.D., et la Présidente/CMO Jane Huang, M.D. La session sera disponible via un webcast sur le site Internet de l'entreprise et archivée pendant 90 jours.
Prelude Therapeutics se spécialise dans l'oncologie de précision, développant des médicaments innovants pour répondre aux besoins élevés non satisfaits des patients atteints de cancer. Leur portefeuille comprend des dégradateurs SMARCA2 de première classe (IV et oral) et un inhibiteur de CDK9. L'entreprise fait également progresser des ADC de précision grâce à des partenariats.
Prelude Therapeutics (Nasdaq: PRLD) hat seine Teilnahme am bevorstehenden Citizens JMP Securities Hämatologie- und Onkologie-Gipfel angekündigt, der für den 2. Dezember 2024 geplant ist. Die virtuelle Veranstaltung wird um 11:30 Uhr ET eine angeregte Diskussion mit CEO Kris Vaddi, Ph.D., und Präsidentin/CMO Jane Huang, M.D. beinhalten. Die Sitzung wird über ein Webcast auf der Unternehmenswebsite verfügbar sein und für 90 Tage archiviert.
Prelude Therapeutics hat sich auf präzise Onkologie spezialisiert und entwickelt innovative Medikamente für die stark unzureichten Bedürfnisse von Krebspatienten. Ihr Produktportfolio umfasst bahnbrechende SMARCA2-Zersetzer (sowohl IV als auch oral) und einen CDK9-Hemmer. Das Unternehmen fördert außerdem Precision ADCs durch Partnerschaften.
- None.
- None.
WILMINGTON, Del., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens JMP Securities Hematology and Oncology Summit, taking place virtually on December 2, 2024.
On Monday, December 2, at 11:30 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, and Jane Huang, M.D., President and Chief Medical Officer, will participate in a fireside chat.
A live webcast of the fireside chat can be accessed on the Company’s website under Events and Presentations. The recording will be archived and available on the Company’s website for 90 days.
About Prelude Therapeutics
Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com.
Investor Contact:
Robert Doody
Senior Vice President, Investor Relations
Prelude Therapeutics
484.639.7235
RDoody@preludetx.com
FAQ
When is Prelude Therapeutics (PRLD) presenting at the Citizens JMP Securities Summit?
What type of drugs is Prelude Therapeutics (PRLD) developing?
How long will the webcast of Prelude Therapeutics' (PRLD) presentation be available?
Who will represent Prelude Therapeutics (PRLD) at the Citizens JMP Securities Summit?
